SAR3419 in Acute Lymphoblastic Leukemia

Stopped early · Phase 2

Conditions studied: Acute Lymphocytic Leukaemia

In brief

Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: * Response duration * Progression Free Survival * Minimal residual disease * Safety * Pharmacokinetics

Key facts

Study ID

NCT01440179

Run by

Sanofi

People needed

100

Starts

2011-10-01

Expected to finish

2014-05-01

Last updated by the study team

2022-09-21

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previously treated Acute Lymphoblastic Leukemia of B cell origin (including Burkitt's lymphoma) in relapse or primary refractory. Patients in first relapse will be eligible regardless of the first remission duration.
• No more than 3 prior salvage therapies.
• Philadelphia positive patients failing treatment with imatinib mesylate are accepted.
• CD19 positive patients.

You may not qualify if…

• None
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 840006 — Denver, Colorado, United States
• Investigational Site Number 840003 — Nashville, Tennessee, United States
• Investigational Site Number 840001 — Houston, Texas, United States
• Investigational Site Number 840002 — San Antonio, Texas, United States
• Investigational Site Number 840004 — Milwaukee, Wisconsin, United States
• Investigational Site Number 250006 — Amiens, France
• Investigational Site Number 250001 — Paris, France
• Investigational Site Number 250002 — Pessac, France
• Investigational Site Number 250008 — Pierre-Bénite, France
• Investigational Site Number 250004 — Rennes, France
• Investigational Site Number 250005 — Strasbourg, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.